← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kalyra Pharmaceuticals, Inc.
San Diego, CA
$3,152,290
Total funding
3
Grants
Funding over time
peak $1.7M · FY2015–18$2M$1.5M$1M$500K$0
'15
'16
'17
'18
Funding mix
By agency
NIH$3,152,290 · 3
By mechanism
R44$2,846,129 · 2
R43$306,161 · 1
Investigators at Kalyra Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A new class of non-opioid analgesics for use in chronic pain management$1,242,938
R44 · FY2015 · DA
A new class of non-opioid analgesics for use in chronic pain management$1,131,822
R44 · FY2016 · DA
A New Treatment to Reduce Scarring$306,161
R43 · FY2016 · GM
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$297,555
R44 · FY2016 · CA
A new class of non-opioid analgesics for use in chronic pain management$94,924
R44 · FY2017 · DA
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$78,890
R44 · FY2018 · CA